diabetes
Novo Nordisk UK appoints George Godfrey as Senior Director, Medical & Regulatory
Godfrey previously served as Head of Medical for Respiratory and Immunology for AstraZeneca UK
Novo Nordisk’s Awiqli approved by US FDA as once-weekly basal insulin for patients with type 2 diabetes
The insulin is designed as an alternative to daily basal insulin
Novo Nordisk elects employee representatives to Board of Directors
The elected employee representatives will join the Board of Directors after the annual general meeting on 26 March 2026
Novo Nordisk to invest 432m euros to expand manufacturing facility in Ireland
Construction is expected to be completed in phases from the end of 2027 into 2028
Novo Nordisk and Vivtex partner in deal worth up to $2.1bn
The companies aim to develop next-generation oral medicines for obesity and diabetes
Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic
The reduction in price to $675 will take effect at the beginning of next year
AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies
Almost three billion people globally are thought to be either overweight or obese
Novo Nordisk and Aspect Biosystems expand collaboration on diabetes research
The companies are working together on cellular medicines to boost, replace or repair biological functions
Novo Nordisk’s Wegovy higher dose injection approved by UK MHRA for obesity
Obesity affects approximately 15 million people in the UK
Novo Nordisk’s Wegovy approved by FDA as oral medication for weight management
Those taking the 25mg pill lost a similar amount of weight as those using injectable Wegovy 2.4mg
Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease
While the trials did not meet their primary endpoints, they highlighted important biomarker findings
Reframing the Obesity Conversation: Key Takeaways from ObesityWeek® 2025
As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector collaboration driving innovation. At ObesityWeek® 2025 in Atlanta, experts from across Inizio reflected...